Agilon health, inc. filed a Form 10-Q with the SEC on November 4, 2026, covering the quarterly period ended September 30, 2026, reporting a swing to profitability in both the third quarter and the nine-month period compared to the prior year.

Key Highlights

  • Net income of $34.9 million for the three months ended September 30, 2026, compared to a net loss of $110.2 million in the same period of 2025, according to the filing.
  • Nine-month net income of $101.8 million for the period ended September 30, 2026, versus a net loss of $202.5 million for the nine months ended September 30, 2025.
  • Total revenues of $1.519 billion for the third quarter of 2026, up from $1.435 billion in the third quarter of 2025.
  • Accumulated deficit narrowed to $1.876 billion as of September 30, 2026, from $1.978 billion as of December 31, 2025.
  • Total stockholders' equity of $280.9 million as of September 30, 2026, compared to $126.7 million as of December 31, 2025.
  • 16,795,774 shares of common stock outstanding as of October 29, 2026, per the filing.
  • Discontinued operations contributed $19.0 million in adjustments on sale of assets, net, for the nine months ended September 30, 2026.

Agilon Health's Third-Quarter 2026 Financial Results: Revenue Growth and Return to Profitability

According to the Form 10-Q filed by agilon health, inc. (NYSE:AGL) for the quarterly period ended September 30, 2026, the company reported total revenues of $1.519 billion for the third quarter of 2026, compared to $1.435 billion in the third quarter of 2025. Medical services revenue, the largest revenue component, reached $1.518 billion in the quarter, up from $1.432 billion a year earlier. For the nine months ended September 30, 2026, total revenues were $4.435 billion, compared to $4.363 billion for the same period in 2025.

The filing disclosed that income from operations for the third quarter of 2026 was $24.1 million, a reversal from a loss from operations of $131.3 million in the third quarter of 2025. For the nine months ended September 30, 2026, income from operations was $39.9 million, compared to a loss from operations of $269.4 million in the prior-year period. The company reported diluted earnings per share from continuing operations of $1.97 for the third quarter of 2026, against a diluted loss per share of $6.65 in the third quarter of 2025. For the nine-month period, diluted earnings per share from continuing operations were $4.81.

As of September 30, 2026, the company reported total assets of $1.566 billion, up from $1.271 billion as of December 31, 2025. Cash and cash equivalents were $174.4 million, and receivables, net, were $1.017 billion. The filing noted that consolidated variable interest entities (VIEs) accounted for total assets of $1.15 billion and total liabilities of $1.18 billion as of September 30, 2026. Medical claims and related payables stood at $892.3 million. Stock-based compensation expense for the third quarter of 2026 was $18.9 million, according to the stockholders' equity table in the filing.

What Was Disclosed

Agilon health, inc. disclosed its unaudited condensed consolidated financial results for the three and nine months ended September 30, 2026, showing a return to net income, growth in revenues, and an improvement in stockholders' equity relative to December 31, 2025.